심근경색 진단 시장 - 세계 시장 예측(2026-2032년)

The Heart Attack Diagnostics Market is projected to grow by USD 27.70 billion at a CAGR of 7.99% by 2032.

Heart Attack Diagnostics Executive Summary

Heart attack diagnostics are central to reducing preventable cardiovascular mortality, accelerating treatment decisions, and improving outcomes for patients presenting with chest pain or other symptoms of acute coronary syndrome. The diagnostic pathway increasingly combines high-sensitivity cardiac troponin testing, electrocardiography, clinical risk scores, imaging, point-of-care testing, and digital decision support to identify myocardial infarction rapidly and distinguish it from non-cardiac causes. Cardiovascular disease remains the leading cause of death worldwide, and ischemic heart disease continues to account for a major share of global mortality, making timely and accurate diagnosis a priority for hospitals, emergency departments, laboratories, and health systems.

The heart attack diagnostics landscape is being shaped by the shift from symptom-led assessment to biomarker-driven and algorithm-supported triage. High-sensitivity troponin assays have enabled earlier rule-in and rule-out protocols, while emergency care systems are adopting structured chest pain pathways to reduce unnecessary admissions and shorten time to intervention. Demand is also rising for rapid testing platforms, integrated laboratory workflows, and connected diagnostic tools that support emergency medicine, cardiology, and primary care coordination. As populations age and the burden of diabetes, hypertension, obesity, and chronic kidney disease increases, the need for reliable myocardial infarction diagnostics is expanding across high-income and emerging healthcare systems alike.

Transformative Shifts in the Heart Attack Diagnostics Landscape

The heart attack diagnostics ecosystem is undergoing transformative change as care moves toward faster, more standardized, and more patient-centered acute cardiac assessment. Traditional diagnostic models that relied heavily on serial clinical observation are being replaced by accelerated diagnostic protocols using high-sensitivity cardiac troponin at presentation and repeated testing within short intervals. These pathways are improving the ability to safely rule out myocardial infarction in low-risk patients while prioritizing invasive evaluation for those at high risk.

Another important shift is the growing role of point-of-care testing and decentralized diagnostics. Emergency departments, ambulances, urgent care centers, and remote clinics are evaluating tools that reduce turnaround time and support earlier clinical decisions. Imaging is also evolving, with coronary computed tomography angiography increasingly used in selected patients with stable or intermediate-risk presentations, while echocardiography and cardiac magnetic resonance imaging help clarify complex cases such as myocarditis, stress cardiomyopathy, or infarction with non-obstructive coronary arteries.

Operationally, healthcare providers are aligning diagnostics with value-based care goals. Reducing door-to-balloon time, minimizing missed myocardial infarction, avoiding unnecessary admissions, and improving laboratory efficiency are now core performance priorities. Regulatory and clinical guideline updates continue to emphasize validated assays, assay-specific thresholds, sex-specific interpretation where appropriate, and integration of diagnostics into evidence-based clinical pathways.

Cumulative Impact of Artificial Intelligence on Heart Attack Diagnostics

Artificial intelligence is having a cumulative impact on heart attack diagnostics by improving signal interpretation, clinical risk stratification, workflow prioritization, and decision support. AI-enabled electrocardiogram analysis can assist clinicians in detecting subtle ischemic patterns, rhythm abnormalities, and high-risk presentations that may be difficult to identify in busy acute care settings. Machine learning models are also being applied to combine troponin kinetics, demographics, comorbidities, vital signs, symptoms, and prior medical history to support more precise chest pain triage.

AI is particularly relevant in emergency departments where diagnostic speed and accuracy directly influence patient outcomes. Algorithms can flag patients at elevated risk, support protocol adherence, and reduce variation in decision-making. In laboratory medicine, AI and automation can help optimize sample routing, quality control, and result escalation, especially for high-sensitivity troponin workflows that depend on reliable timing and interpretation. In imaging, AI-assisted analysis of cardiac computed tomography, echocardiography, and magnetic resonance imaging is improving efficiency in lesion detection, ventricular function assessment, and prioritization of urgent cases.

Despite its promise, AI adoption in heart attack diagnostics requires rigorous clinical validation, bias assessment, interoperability with electronic health records, and transparent governance. Because acute coronary syndrome presents differently by age, sex, ethnicity, and comorbidity profile, AI tools must be evaluated across diverse populations. The strongest near-term value lies in augmenting clinician judgment rather than replacing it, particularly in time-sensitive diagnostic environments.

Key Regional Insights for Heart Attack Diagnostics

Asia-Pacific is experiencing a rising need for heart attack diagnostics as urbanization, aging populations, diabetes, hypertension, smoking, and dietary transitions contribute to cardiovascular disease burden. China, India, Japan, South Korea, Australia, and ASEAN health systems are expanding access to cardiac biomarkers, emergency care networks, catheterization services, and digital health infrastructure. The region shows strong variation in diagnostic capacity, with advanced hospital systems using high-sensitivity troponin and imaging-based pathways while rural and lower-resource settings continue to prioritize affordable point-of-care diagnostics and improved referral networks.

North America remains a highly protocol-driven environment for acute myocardial infarction diagnosis, supported by widespread emergency department access, established cardiac care networks, high-sensitivity troponin adoption, electronic health record integration, and guideline-based chest pain pathways. The United States and Canada emphasize rapid triage, quality metrics, early reperfusion strategies, and reduction of avoidable hospital admissions, making diagnostic accuracy and turnaround time central to clinical and operational performance.

Latin America faces a dual challenge of increasing cardiovascular risk and unequal access to timely diagnostic services. Brazil and Mexico are strengthening emergency cardiac care, but disparities persist between urban tertiary centers and underserved rural or peri-urban populations. Improved availability of cardiac biomarkers, ECG access, ambulance triage, and telemedicine-supported referral pathways are critical to reducing delays in myocardial infarction diagnosis.

Europe benefits from mature cardiovascular guidelines, broad use of high-sensitivity troponin, and strong emergency medicine and cardiology collaboration. Countries across the region are implementing accelerated rule-out protocols, quality-controlled laboratory systems, and integrated imaging pathways. Differences remain in resource allocation and access across Western, Southern, Central, and Eastern Europe, but harmonized clinical guidance supports consistent diagnostic standards.

The Middle East is investing in advanced hospital infrastructure, emergency medicine modernization, and cardiovascular specialty care, particularly in Gulf countries with high rates of diabetes and metabolic syndrome. Demand for rapid and accurate heart attack diagnostics is closely tied to national health transformation programs, tertiary care expansion, and growing attention to preventive cardiology.

Africa continues to face significant diagnostic access gaps due to limited laboratory capacity, delayed emergency presentation, shortages of specialized cardiac services, and competing infectious disease and maternal health priorities. However, the increasing burden of hypertension, diabetes, and urban cardiovascular risk is driving interest in affordable ECG access, point-of-care troponin testing, telecardiology, and strengthened referral systems to improve early detection and treatment of myocardial infarction.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries are seeing growing demand for heart attack diagnostics as cardiovascular risk factors increase alongside rapid urbanization and lifestyle change. Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines vary considerably in hospital infrastructure and laboratory access, creating opportunities for scalable diagnostic models that combine emergency ECG, cardiac troponin testing, referral coordination, and telemedicine-supported interpretation.

The GCC is characterized by a high prevalence of diabetes, obesity, and metabolic syndrome, all of which increase the need for robust acute coronary syndrome diagnostics. Health systems in the group are investing in tertiary care hospitals, emergency medical services, digital health platforms, and specialized cardiology pathways. Rapid cardiac biomarker testing, integrated emergency workflows, and preventive risk identification are prominent priorities.

The European Union benefits from coordinated clinical guidance, mature laboratory standards, and broad adoption of high-sensitivity cardiac troponin testing. EU health systems are focusing on protocolized chest pain assessment, equitable access across member states, laboratory quality assurance, and data-enabled care pathways. Cross-border emphasis on patient safety and clinical evidence supports consistent diagnostic practice.

BRICS countries represent a diverse heart attack diagnostics environment, with China and India facing very large patient volumes, Brazil and South Africa addressing access disparities, and Russia managing cardiovascular mortality through established hospital networks and regional modernization efforts. Across BRICS, the most important priorities include expanding biomarker availability, strengthening emergency response, improving rural access, and supporting affordable diagnostic innovation.

G7 countries generally operate advanced diagnostic ecosystems with high levels of hospital laboratory automation, guideline-based emergency care, cardiovascular imaging, and electronic health record integration. The group is increasingly focused on refining high-sensitivity troponin algorithms, incorporating AI-enabled ECG and imaging support, and reducing diagnostic variation across care settings.

NATO countries include a broad set of healthcare systems where rapid emergency response, military medical readiness, and civilian cardiac care infrastructure intersect. Heart attack diagnostics within these nations are influenced by investments in emergency medicine, interoperability, trauma and acute care logistics, and digital health systems that can support faster triage and coordinated treatment during routine care and crisis conditions.

Key Country Insights for Heart Attack Diagnostics

The United States has a highly developed heart attack diagnostics environment shaped by emergency department protocols, high-sensitivity troponin use, chest pain centers, integrated electronic health records, and quality measures for acute myocardial infarction care. Canada emphasizes standardized acute coronary syndrome pathways, equitable access across provinces, and use of laboratory-based and imaging-supported diagnosis, with special attention to service delivery across geographically dispersed communities. Mexico is strengthening cardiovascular diagnostics through public and private healthcare investment, though timely access to emergency ECG, troponin testing, and interventional cardiology remains uneven across regions.

Brazil faces a substantial cardiovascular disease burden and continues to expand acute cardiac care capacity across public and private systems. Diagnostic priorities include improving emergency recognition, biomarker access, ambulance pathways, and referral to specialized centers. The United Kingdom has widely implemented evidence-based chest pain assessment, high-sensitivity troponin protocols, and national clinical guidance to improve early rule-out and rule-in of myocardial infarction. Germany benefits from advanced hospital infrastructure, strong laboratory medicine, and broad access to cardiology services, supporting sophisticated biomarker and imaging workflows. France emphasizes structured emergency care, cardiac intensive care access, and guideline-aligned diagnostics, while Italy and Spain continue to apply high-sensitivity troponin and imaging pathways within national and regional healthcare systems. Russia has focused on cardiovascular mortality reduction through emergency care modernization, regional vascular centers, and improved access to diagnostic and interventional services.

China is expanding heart attack diagnostics through major investments in hospital capacity, chest pain center development, high-sensitivity biomarker testing, and digital health integration, while addressing gaps between major cities and lower-tier regions. India faces a growing burden of premature coronary artery disease, making affordable and rapid diagnostics essential across public hospitals, private networks, and rural care settings. Japan has an aging population and a mature cardiovascular care system, supporting high-quality laboratory diagnostics, imaging, and emergency response. Australia combines evidence-based chest pain pathways, high-sensitivity troponin use, and telehealth-supported regional care to address distance-related access challenges. South Korea has advanced hospital technology, strong cardiac care infrastructure, and increasing adoption of digital and AI-enabled diagnostic support for acute cardiovascular presentations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize diagnostic speed, clinical reliability, and workflow integration across the entire acute cardiac care pathway. Investment should focus on validated high-sensitivity cardiac troponin assays, point-of-care solutions with strong analytical performance, ECG interpretation support, and interoperability with hospital information systems and electronic health records. Products and services should be designed to support guideline-based accelerated diagnostic protocols, including clear timing, result interpretation, and escalation pathways.

Healthcare stakeholders should also address access gaps by tailoring diagnostic solutions to different care settings. Advanced hospitals need integrated laboratory automation, AI-enabled decision support, and imaging workflow optimization, while rural and resource-constrained facilities require affordable, durable, and easy-to-use testing platforms supported by training and referral systems. Developers of AI tools should emphasize transparent validation, representative datasets, clinical usability, and post-deployment monitoring to ensure safe performance across diverse patient populations.

Strategic priorities include partnerships with emergency medicine and cardiology teams, education on sex-specific and age-sensitive diagnostic interpretation, support for quality metrics, and evidence generation demonstrating reductions in time to diagnosis, missed myocardial infarction, unnecessary admissions, and operational bottlenecks. Leaders that align innovation with real-world clinical pathways will be better positioned to improve patient outcomes and strengthen adoption.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in verified public health, clinical, and regulatory evidence. The analysis draws on peer-reviewed cardiology literature, international cardiovascular guidelines, public health datasets, clinical consensus statements, hospital care standards, regulatory information, and recognized evidence on acute coronary syndrome diagnosis. Key topics evaluated include high-sensitivity cardiac troponin testing, electrocardiography, emergency department chest pain pathways, cardiac imaging, point-of-care diagnostics, AI-enabled decision support, and regional healthcare access trends.

The research approach emphasizes triangulation across multiple evidence sources to ensure consistency and reliability. Clinical insights are interpreted through the lens of current diagnostic practice, including validated biomarker algorithms, guideline-directed patient stratification, laboratory quality requirements, and emergency care workflows. Regional, group, and country insights are assessed based on cardiovascular disease burden, healthcare infrastructure, diagnostic access, emergency response capacity, technology adoption, and public health priorities.

The scope intentionally excludes market estimation, market sizing, market share, and forecasting. The objective is to provide an evidence-based strategic overview of heart attack diagnostics, focusing on clinical relevance, technology evolution, regional dynamics, and actionable implications for healthcare and diagnostic industry stakeholders.

Conclusion

Heart attack diagnostics are evolving from fragmented, time-intensive assessment toward faster, biomarker-led, digitally supported, and protocolized care. High-sensitivity troponin testing, ECG interpretation, imaging, point-of-care diagnostics, and AI-enabled decision support are reshaping how clinicians identify myocardial infarction, rule out low-risk presentations, and prioritize urgent intervention. The most important value drivers are diagnostic accuracy, speed, interoperability, clinical validation, and equitable access.

Regional needs differ significantly. Advanced health systems are refining accelerated pathways and AI-supported workflows, while emerging and underserved settings require broader access to reliable ECG, troponin testing, emergency transport, and referral networks. Across all markets, the burden of cardiovascular disease and the complexity of acute coronary syndrome presentations reinforce the need for dependable diagnostic infrastructure.

Organizations that align heart attack diagnostic innovation with real-world emergency care pathways, validated clinical evidence, and diverse patient needs will be best positioned to support better outcomes. The future of myocardial infarction diagnosis will depend on integrating laboratory precision, digital intelligence, clinical judgment, and health system readiness into a seamless acute care model.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Heart Attack Diagnostics Market, by Product Type

• 7.1. Introduction
• 7.2. Biomarker Testing
  • 7.2.1. CK-MB
  • 7.2.2. Troponin I
  • 7.2.3. Troponin T
• 7.3. Electrocardiography
  • 7.3.1. Resting ECG
  • 7.3.2. Stress ECG
• 7.4. Imaging
  • 7.4.1. Computed Tomography
  • 7.4.2. Magnetic Resonance Imaging

8. Heart Attack Diagnostics Market, by Technology

• 8.1. Introduction
• 8.2. Laboratory Based
  • 8.2.1. High Sensitivity Troponin Assay
  • 8.2.2. Immunoassay
• 8.3. Point Of Care
  • 8.3.1. Handheld Devices
  • 8.3.2. Portable Devices

9. Heart Attack Diagnostics Market, by Application

• 9.1. Introduction
• 9.2. Acute Detection
• 9.3. Risk Assessment
• 9.4. Secondary Prevention

10. Heart Attack Diagnostics Market, by End User

• 10.1. Introduction
• 10.2. Ambulatory Care Centers
• 10.3. Diagnostic Centers
• 10.4. Home Care
• 10.5. Hospitals

11. Heart Attack Diagnostics Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Heart Attack Diagnostics Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Heart Attack Diagnostics Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. FPNV Positioning Matrix, 2025
• 14.3. Market Concentration Analysis, 2025
  • 14.3.1. Concentration Ratio (CR)
  • 14.3.2. Herfindahl Hirschman Index (HHI)
• 14.4. Recent Developments & Impact Analysis, 2025
• 14.5. Product Portfolio Analysis, 2025
• 14.6. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Agilent Technologies, Inc.
• 15.2. Avid Bioservices, Inc.
• 15.3. Bio-Rad Laboratories, Inc.
• 15.4. BioAgilytix Labs
• 15.5. BiomarkerBay B. V.
• 15.6. Bristol Myers Squibb
• 15.7. Eurofins Scientific SE
• 15.8. F. Hoffmann-La Roche AG
• 15.9. Icon PLC
• 15.10. Intertek Group PLC
• 15.11. IQVIA
• 15.12. JSR Life Sciences, LLC
• 15.13. KCAS Group
• 15.14. Laboratory Corporation of America Holdings
• 15.15. Merck KGaA
• 15.16. Myriad Genetics, Inc.
• 15.17. NeoGenomics Laboratories
• 15.18. Parexel International Corporation
• 15.19. PerkinElmer Inc.
• 15.20. Randox Laboratories
• 15.21. SGS S.A.
• 15.22. Shuwen Biotech Co., Ltd.
• 15.23. Syneos Health
• 15.24. Thermo Fisher Scientific, Inc.
• 15.25. WuXi Biologics Inc.